MLEC (Moolec Science) 1-Year Sharpe Ratio: -0.35 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLEC Moolec Science SA MLEC
44 GF Score
Price $7.00
GF Value $84.84
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Moolec Science 1-Year Sharpe Ratio?

Moolec Science MLEC -1.41% 44 1-Year Sharpe Ratio is -0.35 as of Jul. 17, 2026. GuruFocus rates MLEC with a GF Score™ of 44/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-17), Moolec Science's 1-Year Sharpe Ratio is -0.35.

Moolec Science  (NAS:MLEC) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Moolec Science 1-Year Sharpe Ratio Related Terms

MLEC vs GNPX, ADIL, APVO: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Moolec Science's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moolec Science 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moolec Science's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Moolec Science's 1-Year Sharpe Ratio falls into.


MLEC
44GF Score
Moolec Science SA MLEC
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moolec Science 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.35 mean?
Moolec Science (MLEC) has a 1-Year Sharpe Ratio of -0.35 as of Jul. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Moolec Science and its competitors.
Is Moolec Science's 1-Year Sharpe Ratio too high?
Moolec Science's current 1-Year Sharpe Ratio is -0.35. Overall, Moolec Science has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's 1-Year Sharpe Ratio compare to GNPX and ADIL?
Moolec Science's 1-Year Sharpe Ratio of -0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Moolec Science and its competitors. Moolec Science's current 1-Year Sharpe Ratio is -0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.00 — trading 91.7% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.35. Moolec Science's overall GF Score™ is 44/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Moolec Science (MLEC), the current 1-Year Sharpe Ratio is -0.35 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moolec Science (MLEC) Overvalued in 2026?

Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued. The current stock price of $7.00 is trading 91.7% below its estimated GF Value™ of $84.84. GuruFocus considers Moolec Science to be Possible Value Trap.

Key valuation signals for MLEC:

  • 1-Year Sharpe Ratio: -0.35
  • GF Value™: $84.84 vs. price of $7.00 (91.7% below fair value)
  • GF Score™: 44/100 with 9 warning signs

No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moolec Science Business Description

Address c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, CYM, KY1-9009
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
44GF Score

Get the complete analysis for MLEC

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$84.84
GF Value